Selecta Biosciences, Inc. (NASDAQ:SELB) Q3 2018 Earnings Conference Call Transcript

Nov 08, 2018 • 08:30 am ET

Previous

Selecta Biosciences, Inc. (NASDAQ:SELB) Q3 2018 Earnings Conference Call Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Thank you for holding. Welcome to the Selecta Biosciences Third Quarter 2018 Conference Call. (Operator Instructions) This call is being webcast live on the Investors and Media section of Selecta's website at www.selectabio.com, and it is being recorded.

For opening remarks, I would now like to turn the call over to John Leaman, Selecta's CFO and Head of Corporate Strategy. Please go ahead.

Executive
John Leaman

Thank you, and good morning, everyone. Earlier today, we issued a press release containing our third quarter 2018 financial results and other corporate updates, and we filed our 10-Q. This release and the 10-Q can be accessed by visiting our website at www.selectabio.com. I'm joined today by CEO Werner Cautreels; our Chief Commercial Officer Stephen Smolinski; and other members of the management will be joining us for the Q&A portion of the call.

Before we get started, we'd like to advise that certain remarks that are made during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of Selecta's most recent quarterly report on Form 10-Q filed with the SEC, which can also be accessed at selectabio.com.

In addition, any forward-looking statements represent the company's views only as of today, November 8, 2018, and should not be relied upon as representing the company's views as of any subsequent date. While Selecta may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if management's views change.

Now let me introduce Werner, who will kick things off.

Executive
Werner Cautreels

Thank you, John, and good morning, everyone. We believe this year's accomplishments make us well positioned to achieve several important upcoming milestones. In particular, our lead program, SEL-212, for the treatment of chronic severe gout patients, has generated a robust clinical package in our Phase II clinical study that shows, based on clinical data collected to date, it has the potential to fulfill several unmet needs in chronic severe gout patients, including sustained serum uric acid reduction, reduced flares and convenient once-monthly dosing. We believe that if approved, SEL-212 could change the treatment paradigm for patients with chronic severe gout who are in real need of new therapeutic options.

Let me now take you through the data that gives us confidence going into the start of a head-to-head superiority trial against KRYSTEXXA, the current FDA-approved uricase therapy, in the first quarter of next year. Just as a reminder, SEL-212 is a combination of SVP-Rapamycin, our novel immune tolerance technology, and pegadricase, our proprietary pegylated uricase. In October 2018, we presented data from new cohorts of patients receiving five monthly combination doses of SEL-212 in our ongoing Phase II study at ACR in Chicago.

Projections based on the trending of data collected to date